[go: up one dir, main page]

BR0308634A - Uso de um adenovìrus, e, composição - Google Patents

Uso de um adenovìrus, e, composição

Info

Publication number
BR0308634A
BR0308634A BR0308634-8A BR0308634A BR0308634A BR 0308634 A BR0308634 A BR 0308634A BR 0308634 A BR0308634 A BR 0308634A BR 0308634 A BR0308634 A BR 0308634A
Authority
BR
Brazil
Prior art keywords
adenovirus
composition
rnas
vai
mutations
Prior art date
Application number
BR0308634-8A
Other languages
English (en)
Inventor
Ramon Alemany Bonastre
Manel Maria Cascallo Piqueras
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of BR0308634A publication Critical patent/BR0308634A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10364—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"USO DE UM ADENOVìRUS, E, COMPOSIçãO". A presente invenção diz respeito à utilização de um adenovírus para o tratamento do câncer. A invenção é caracterizada pelo fato de que o adenovírus é defeituoso em seus RNAs vírus-associados (VA), referidos adenovírus tendo uma mutação na seq³ência do gene VAI ou VAII, ou de ambos. Referido adenovírus também pode ter uma mutação nas seq³ências que controlam a expressão dos RNAs VA.
BR0308634-8A 2002-03-26 2003-03-25 Uso de um adenovìrus, e, composição BR0308634A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200716 2002-03-26
PCT/ES2003/000140 WO2003080083A1 (es) 2002-03-26 2003-03-25 Uso de adenovirus mutados en los genes va para el tratamiento del cancer

Publications (1)

Publication Number Publication Date
BR0308634A true BR0308634A (pt) 2005-02-15

Family

ID=27772025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308634-8A BR0308634A (pt) 2002-03-26 2003-03-25 Uso de um adenovìrus, e, composição

Country Status (13)

Country Link
US (3) US7344711B2 (pt)
EP (2) EP1605053A1 (pt)
JP (2) JP2005526099A (pt)
AT (1) ATE309812T1 (pt)
AU (1) AU2003226835B2 (pt)
BR (1) BR0308634A (pt)
CA (1) CA2478616C (pt)
DE (1) DE60302350T2 (pt)
DK (1) DK1498129T3 (pt)
ES (1) ES2248764T3 (pt)
IL (2) IL163745A0 (pt)
MX (1) MXPA04009204A (pt)
WO (1) WO2003080083A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1605053A1 (en) * 2002-03-26 2005-12-14 Oncolytics Biotech Inc. Use of adenoviruses mutated in the VA genes for cancer treatment
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int ATTENUATED REOVIRUS
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
ES2355882B1 (es) 2009-03-24 2012-02-13 INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer.
WO2012121071A1 (ja) * 2011-03-04 2012-09-13 国立大学法人大阪大学 VA-RNAsが発現しないアデノウイルスベクター
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP3198009B1 (en) 2014-09-24 2021-09-08 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2019199859A1 (en) 2018-04-09 2019-10-17 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
AU2021324483A1 (en) 2020-08-10 2023-04-13 Mesoblast International Sàrl Cellular compositions and methods of treatment
AU2023361162A1 (en) 2022-10-11 2025-05-29 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648301B2 (ja) * 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 真核細胞の形質転換のための補助ｄｎａを含むベクター
US5079159A (en) * 1983-12-27 1992-01-07 Genetics Institute, Inc. Method for making tissue plasminogen activator
US5002874A (en) * 1987-09-17 1991-03-26 Genetics Institute, Inc. Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
BR0015491A (pt) * 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
WO2003022311A1 (en) * 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
EP1605053A1 (en) * 2002-03-26 2005-12-14 Oncolytics Biotech Inc. Use of adenoviruses mutated in the VA genes for cancer treatment
EP1567198A4 (en) * 2002-12-02 2006-05-31 Genvec Inc MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES

Also Published As

Publication number Publication date
IL163745A (en) 2010-02-17
ES2248764T3 (es) 2006-03-16
AU2003226835A1 (en) 2003-10-08
IL163745A0 (en) 2005-12-18
MXPA04009204A (es) 2004-11-26
US20080089864A1 (en) 2008-04-17
EP1605053A1 (en) 2005-12-14
EP1498129A1 (en) 2005-01-19
US20060233753A1 (en) 2006-10-19
CA2478616A1 (en) 2003-10-02
US7344711B2 (en) 2008-03-18
DE60302350T2 (de) 2006-08-03
CA2478616C (en) 2012-05-29
WO2003080083A1 (es) 2003-10-02
AU2003226835B2 (en) 2006-11-09
JP2010184940A (ja) 2010-08-26
HK1071060A1 (en) 2005-07-08
EP1498129B1 (en) 2005-11-16
US20090202489A2 (en) 2009-08-13
DK1498129T3 (da) 2006-04-03
JP2005526099A (ja) 2005-09-02
DE60302350D1 (de) 2005-12-22
US20110053249A1 (en) 2011-03-03
ATE309812T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
BR0308634A (pt) Uso de um adenovìrus, e, composição
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
GEP20125594B (en) Sclerostin binding agents
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
MX2009004510A (es) Oligorribonucleotidos y sus usos.
SG157422A1 (en) Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
ATE508188T1 (de) Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
ATE516052T1 (de) Zusammensetzungen für knochenzemente enthaltend eine nichtpolymerisierbare organoiodverbindung
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
TW200716088A (en) Formulations and methods for treating amyloidosis
AU2002359645A8 (en) Targeted genetic risk-stratification using microarrays
MX2008000059A (es) Marcadores de fibrosis.
WO2004110365A3 (en) Liver related disease compositions and methods
WO2006107946A3 (en) Bone cement compositions and the like comprising an rnaiii-inhibiting peptide
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
EP1978994A4 (en) BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
MXPA05008817A (es) Derivados de esteres lipidos de nucleotidos.
MXPA05012742A (es) Composiciones de tratamiento para el cabello.
WO2006015191A3 (en) Multicyclic lonidamine analogs
NO20022148D0 (no) Ikke-viralt genleveringssystem
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
AU2003256284A1 (en) Rapidly disintegrating formulations for treating or preventing mucositis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.